Rossari Biotech Steady Financial Growth with Strong Market PosRossari Biotech has demonstrated consistent financial growth, with its revenue increasing from ₹516 crores in FY2019 to ₹1,910 crores in the trailing twelve months (TTM) of FY2024. The company has maintained a stable operating profit margin around 13-17% over the years, reflecting its efficient cost management and strong market position. Although the return on equity (ROE) has slightly decreased to 13% in the most recent fiscal year, it remains a solid performer within the specialty chemicals sector. Additionally, Rossari's conservative dividend payout and strategic reinvestment into the business indicate a focus on long-term growth.
I am buying at 900-915 zone with a stop loss at 790 for a target of 1250-1600+
Disclaimer: The information provided here is intended for informational purposes only and should not be construed as investment advice or a recommendation to buy or sell any securities. The opinions expressed are those of the author and are subject to change without notice. Past performance is not indicative of future results. Investors should consult their financial advisors before making any investment decisions. Trading and investing in financial markets involve risks, including the loss of principal. Neither the author nor any of their affiliates shall be held liable for any loss or damage resulting from the use of this information.
